Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy

Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following... Skeletal Radiol (2017) 46:1385–1395 DOI 10.1007/s00256-017-2706-6 SCIENTIFIC ARTICLE Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy 1 1 1 1 Connie Y. Chang & F. Joseph Simeone & Martin Torriani & Miriam A. Bredella Received: 3 March 2017 /Revised: 14 June 2017 /Accepted: 19 June 2017 /Published online: 30 June 2017 ISS 2017 Abstract (P = 0.02). ICC was almost perfect for average attenuation Purpose Osseous metastases often undergo an osteoblastic and substantial for maximum attenuation. healing response following chemotherapy. The purpose of Conclusion Quantitative assessment of osseous metastatic our study was to demonstrate the quantitative CT changes in disease using CT attenuation measurements demonstrated a attenuation of osseous metastases before and after statistically significant increase in attenuation more than chemotherapy. 12 months after initiation of chemotherapy. Materials and methods Our study was IRB approved and . . HIPAA compliant. Our cohort consisted of 86 consecutive Keywords Osseous metastases Chemotherapy Healing . . . cancer patients with contrast-enhanced CTs before and response CT Attenuation Cancer 14 ± 2 (12–25) months after initiation of chemotherapy (60 ± 11 years, 36 males, 50 females). The average and max- imum metastasis attenuations were measured in Hounsfield Introduction units (HU) by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Skeletal Radiology Springer Journals

Quantitative contrast-enhanced CT attenuation evaluation of osseous metastases following chemotherapy

Loading next page...
 
/lp/springer_journal/quantitative-contrast-enhanced-ct-attenuation-evaluation-of-osseous-WXdEJwGya6
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by ISS
Subject
Medicine & Public Health; Imaging / Radiology; Orthopedics; Pathology; Nuclear Medicine
ISSN
0364-2348
eISSN
1432-2161
D.O.I.
10.1007/s00256-017-2706-6
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial